Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 14/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2073619 | 0.86 | NOTUM (0.56) | NOTUMTDP1GRM5 | |
| SCHEMBL2072056 | 0.84 | NOTUM (0.83) | NOTUMTDP1ALDH1A1LMNAHTT | |
| SCHEMBL3436604 | 0.84 | NOTUM (0.52) | NOTUMTDP1LMNAHSD11B1 | |
| Hydrochloric Acid SCHEMBL5427235 | 0.82 | GAA (0.59) | NOTUMTDP1ALDH1A1HTTSCN9A | |
| SCHEMBL1573476 | 0.81 | NOTUM (0.57) | NOTUM | |
| SCHEMBL23536360 | 0.81 | NOTUM (0.63) | NOTUMTDP1LMNAHTT | |
| SCHEMBL29932011 | 0.81 | NOTUM (0.63) | NOTUMTDP1LMNAHTT | |
| SCHEMBL4403596 | 0.79 | TDP1 (0.74) | TDP1ALDH1A1HTT | |
| SCHEMBL13893331 | 0.79 | NOTUM (0.54) | NOTUMTDP1HSD11B1 | |
| SCHEMBL5800932 | 0.79 | NOTUM (0.81) | NOTUMLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059979-A1 | Piperidine/Cyclohexane Carboxamide Derivatives For Use as Vanilloid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
| EP-1660481-A1 | PIPERIDINE/CYCLOHEXANE CARBOXAMIDE DERIVATIVES FOR USE AS VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005016915-A1 | PIPERIDINE/CYCLOHEXANE CARBOXAMIDE DERIVATIVES FOR USE AS VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059979-A1 | Piperidine/Cyclohexane Carboxamide Derivatives For Use as Vanilloid Receptor Modulators | TRPV1, CNR1, OPRM1 | NOTUM 2450/4885TDP1 4475/4885GRM5 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.